Gregory W. Albers

Clinical Focus

• Neurology

Administrative Appointments

• Coyote Foundation Professor, Neurology and Neurological Sciences (2007 - present)
• Director, Stanford Stroke Center, Stanford Medical Center (1992 - present)

Professional Education

Web Site Links

• Stanford Stroke Center

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. View Full Information

Research Interests

Our group’s research focus is the acute treatment and prevention of cerebrovascular disorders. Our primary interest is the use of diffusion- and perfusion-weighted MRI to expand the treatment window for ischemic stroke. We are also conducting clinical studies of both neuroprotective and thrombolytic strategies for the treatment of acute stroke and investigating new antithrombotic strategies for stroke prevention.

Clinical Trials

• Albumin in Acute Stroke (ALIAS) Trial - Part 2 Recruiting
• Diagnostic Utility of MRI in Intracerebral Hemorrhage Recruiting
• Minimally Invasive Surgery Plus rt-PA for ICH Evacuation (MISTIE) Recruiting
• The Insulin Resistance Intervention after Stroke Trial (IRIS) Recruiting

Publications

• Clinical and radiographic natural history of cervical artery dissections. Schwartz NE, Vertinsky AT, Hirsch KG, Albers GW. J Stroke Cerebrovasc Dis. 2009 Nov-Dec; 18 (6): 416-23
• Stroke Therapy Academic Industry Roundtable (STAIR) recommendations for extended window acute stroke therapy trials. Saver JL, Albers GW, Dunn B, Johnston KC, Fisher M. Stroke. 2009; 40 (7): 2594-600
• Geography, structure, and evolution of diffusion and perfusion lesions in Diffusion and perfusion imaging Evaluation For Understanding Stroke Evolution (DEFUSE). Olivot JM, Mlynash M, Thijs VN, Purushotham A, Kemp S, Lansberg MG, Wechsler L, Gold GE, Bammer R, Marks MP, Albers GW. Stroke. 2009; 40 (10): 3245-51
• Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: subanalysis of the Prevention of VTE after Acute Ischemic Stroke With LMWH (PREVAIL) study. Kase CS, Albers GW, Bladin C, Fieschi C, Gabbai AA, O'Riordan W, Pineo GF. Stroke. 2009; 40 (11): 3532-40
• Improving dynamic susceptibility contrast MRI measurement of quantitative cerebral blood flow using corrections for partial volume and nonlinear contrast relaxivity: A xenon computed tomographic comparative study. Zaharchuk G, Bammer R, Straka M, Newbould RD, Rosenberg J, Olivot JM, Mlynash M, Lansberg MG, Schwartz NE, Marks MM, Albers GW, Moseley ME. J Magn Reson Imaging. 2009; 30 (4): 743-52